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Abstract. Rat C6 glioma is a chemo-resistant experimental
brain tumor that is difficult to treat with various drug com-
binations. Previous studies suggested that imatinib mesylate
(Gleevec) is effective in pre-clinical trials for glioblastoma.
Also, chlorimipramine (Anafranil) is an anti-depressant
drug in use in the clinic and shown to have anti-neoplastic
activity. We hypothesized that treatment of resistant C6
glioma with combination of imatinib and chlorimipramine
may potentiate cytotoxicity and reverse resistance. C6 glioma
was examined both as monolayer and as spheroid cultures.
Several experimental designs were examined all of which
showed synergistic activity albeit at different time kinetics.
Combination treatment resulted in inhibition of cell growth
and enhanced cell death as determined by dye exclusion.
Further, the combination treatment resulted in significant
induction of apoptosis as determined by Annexin V-FITC
and PI. Also, there was inhibition of DNA synthesis and
cAMP. Altogether, these findings supported the anti-
proliferative and cytotoxic effects of the combination
treatment. Morphological studies were also performed using
transmission and scanning electron microscopy. Significant
synergistic apoptosis was detected by the combination
treatment in both the monolayers and spheroid cultures.
There was also a synergistic effect in autophagy by the
combination. Several altered morphological features were
noted by both the individual compound and enhanced by the
combination treatment. The present findings support our
hypothesis and demonstrate the potentiation of cytotoxicity
by the com-bination of imatinib and chlorimipramine in C6
glioma. Further, the findings suggest the potential clinical
application of the combination in the treatment of drug-
resistant glioma.
Introduction
Receptor and non-receptor tyrosine kinases (TKs) have
emerged as clinically useful drug target molecules for treating
cancer (1). Imatinib mesylate (IM; STI-571, Gleevec®) is a
small molecule ATP analogue which is a potent and selective
inhibitor of several protein TKs of the receptors for platelet-
derived growth factor (PDGF), bcr-abl, stem cell factor (SCF),
and c-kit by interacting with the ATP-binding site (2,3). It
has been reported that mitochondria and telomerase are also
targets of imatinib mesylate (4,5). IM was primarily designed
to treat chronic myeloid leukemia (CML), but it is also
currently the drug of choice for the treatment of metastatic
gastrointestinal stromal tumors (GISTs) (6,7). The success of
this compound in the treatment of CML and GISTs has led
to the broader examination of its application in the treatment
of other tumors, such as glioblastoma (8), small lung cancer
(9), anaplastic thyroid cancer (10) and prostate cancer (11).
C6 rat glioma is a chemo-resistant experimental brain
tumor which is difficult to treat with a combination of drugs
(12). This cell line has properties similar to human glio-
blastoma and has been widely used as a model system for
investigation of human glioblastoma (13). Imatinib has
recently been found to be efficacious in preclinical trials for
glioblastoma, but the use of IM has been tempered by the
problems of disease persistence and resistance. It has been
reported that IM inhibits the growth of glioma cells in pre-
clinical models, but its poor brain distribution by P-glyco-
protein (P-gp) limits its efficacy in patients (14,15).
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Chlorimipramine (CIMP; clomipramine or Anafranil®)
is the tricyclic anti-depressant that has been in clinical use
for over 30 years (16). Previous studies which were made
on various types of cancer cells, including drug-resistant
leukemias, renal cancer cells, solid murine tumors, and a
wide range of cell cultures derived from brain tumors,
(e.g., astrocytomas, mixed oligo-astrocytomas, glioblastoma
multiforme, and menningiomas), revealed the novel effect
of CIMP as an anti-neoplastic agent (17-20). From studies
carried out on non-tumorigenic tissues and tumorigenic cell
lines, it has been shown that CIMP inhibits complex-III of
the respiratory chain, resulting in increased ROS, cytochrome
C release and caspase-activated apoptosis (21,22). CIMP
also causes irreversible DNA damage in both normal and
neoplastic cells, but mitochondria damage has only been
observed in neoplastic cells (19). CIMP has been demon-
strated to reverse multidrug resistance (MDR) to conventional
antineoplastic agents, such as doxorubicin, in several tumor
cell lines in vitro (17,19,23,24).
One of the most recent novel developments in chemo-
therapy has been to move away from cytotoxic agents that
inhibit non-specific targets in cellular pathways that contribute
to carcinogenesis and resistance (25,26). The present study
investigated the therapeutic potential of the selective mito-
chondria inhibitor, CIMP, used in combination with IM
for the treatment of malignant C6 glioma cells used as
monolayers and spheroid cultures. This combination of IM
and CIMP has not been previously investigated in vitro or
in vivo.
Materials and methods
Drugs and solutions. The following drugs were used: IM was
kindly provided by Dr E. Buchdunger (Novartis AG, Basel,
Switzerland) and Dr Fulya Dincturk (Novartis AG, Istanbul,
Turkey). CIMP was obtained from Boehringer (Mannheim,
GmbH). IM was prepared as 100 μM stock solution in
phosphate buffered saline (pH 7.2) and filtered through a
0.22 μ injector filter (TPP, Trasadingen, Switzerland) before
use. CIMP was dissolved in 70% ethanol to give a stock
solution of 100 μM.
Monolayer culture. The rat C6 glioma cell line was supplied
by ATCC (Rockville, MD, USA) and was grown in mono-
layers in Dulbecco's Modified Eagle's Medium-F12 (DMEM-
F12; Biological Industries, Haemek, Israel) supplemented
with 10% heat-inactivated foetal calf serum (FCS; Sigma
Chemical Co., St. Louis, MO, USA), 100 units/ml penicilin
and 100 μg/ml streptomycin (both from Sigma Chemical
Co.). Cells in semi-confluent flasks were harvested by using
0.05% trypsin (Sigma Chemical Co.), centrifuged after
adding DMEM-F12 for trypsin inactivation, and resuspended
in DMEM-F12. After trypan blue exclusion, the glioma cells
were plated in 6-well culture plates containing 5 ml DMEM-
F12 medium at a concentration of 5x105 cells/well with
100% viability.
Constitution of a 3-dimensional spheroid model. An in vitro
multicellular C6 glioma spheroid model was established using
the liquid overlay technique. Briefly, once the monolayer
cultures became semi-confluent, the cells were trypsinized and
single cells with 100% viability were cultured over 3% Difco
Noble agar-coated (Becton-Dickinson, Sparks, MD) 6-well
culture plates containing 5 ml DMEM-F12 medium at a
concentration of 1x106 cells/well (27).
Experimental design. The investigated drugs at a volume of
100 μl were applied to monolayers and spheroid cultures
of malignant C6 glioma cells at the following final
concentrations: 1, 10, 100 and 200 μM, except for the control
cells, to which nutrient medium was applied. The cultures
were incubated for 24, 48, 72 and 96 h. The IC50 values of
IM and CIMP were determined as 10 μM. Four sets of
experiments were performed under the following standard
monolayer and spheroid culture conditions: i) untreated
control cells; ii) cells treated with IM; iii) cells treated with
CIMP; and iv) cells treated with a combination of IM and
CIMP at a ratio of 1:1. The effects of drugs, both on mono-
layers and spheroid cultures, were determined by evaluation
of cytotoxicants, including cell proliferation (total cell number),
cell viability by trypan blue exclusion assay, the bromo-
deoxyuridine labelling index (BrDU-LI), spheroid volumes,
morphology by transmission (TEM) and scanning (SEM)
electron microscopy, Annexin V-FITC/PI staining, and
cAMP levels by radioimmunoassay.
Cell cycle kinetics
Analysis of DNA synthesis (S-phase) by BrdU incorporation
for monolayer cultures. C6 rat glioma cells were seeded
on the cover slips and treated with drugs, as described in the
survival studies throughout 96 h at 24-h intervals. Endo-
genous peroxidase activity was quenched with 0.5% H2O2
in methanol. Double-stranded DNA was denatured with
4 N HCl. Following the washings, a non-specific blocking
reagent (Ultra-V-Block; Lab Vision Co., Westinghouse, CA,
USA) was used to prevent non-specific binding. Monoclonal
mouse anti-BrdU antibody (1:50; Lab Vision Co.) was the
primary antibody and the secondary antibody was biotiny-
lated goat anti-mouse antibody (Lab Vision Co.). After
washing, peroxidase-conjugated streptavidin (Lab Vision
Co.) was applied and aminoethyl carbazole was used as a
chromogen. The cover slips were then counterstained with
Mayer's hematoxylin to augment the nuclear staining. BrDU-
labelled cells in the S-phase had red-stained nuclei. For
negative controls, the cover slips of the same groups were
processed with exactly the same steps, excluding the primary
antibody. The BrDU-LI (the number of positively stained
cells divided by the counted total number of cells) was
calculated by evaluating at least 3000 cells in multiple
high power fields.
DNA synthesis (S-phase) analysis by BrdU incorporation for
spheroid cultures. Spheroids were gently removed from the
surface of the solidified agarose. The sections were treated
with 0.1% trypsin for antigen retrieval and incubated in a
solution of 0.3% H2O2. The sections were treated with 4 N
HCl and incubated in 0.1 M Borax. Following the washings,
a non-specific blocking reagent (Ultra-V-Block; Lab Vision
Co.) was used to prevent non-specific binding. Monoclonal
mouse anti-BrdU antibody (1:50; Lab Vision Co.) was the
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primary antibody and the secondary antibody was a
biotinylated goat anti-mouse antibody (Lab Vision Co.).
After washing, peroxidase-conjugated streptavidin (Lab
Vision Co.) was applied and aminoethyl carbazole was used
as a chromogen. The sections were counterstained in Mayer's
hematoxylin. BrDU-labelled cells in S-phase had red-stained
nuclei. Approximately 30 spheroids in each slide were
determined for the calculation of the BrDU-LI. For negative
controls, adjacent sections were processed with exactly the
same steps, excluding the primary antibody.
Annexin V-FITC/PI staining. One of the manifestations of
apoptosis is the translocation of phosphotidylserine (PS)
from the inner membrane to the outer side of the plasma
membrane. Externalization of PS was studied by an Annexin
V binding assay. Briefly, cells were washed with PBS twice
and re-suspended in binding buffer containing 0.01 M HEPES,
0.14 mM NaCl and 2.5 Mm CaCl2. A cell suspension (1x105
cells in 100 μl) in the binding buffer was incubated with 5 μl
of FITC-labeled Annexin V (BD PharMingen, San Diego,
CA) and vital dye propidium iodide for 15 min in the dark at
room temperature. After incubation, the fluorescence of the
cells for propidium iodide (PI) and Annexin V was measured
simultaneously in a BD FACS Calibur and analyzed with the
operating software of the instruments (CellQuest; BD Phar-
Mingen). Data acquisition and analysis were done with the
CellQuest and WinMDI programs.
cAMP levels. Following centrifugation of cultures, the
supernatants were removed and 0.1 N HCl with DMEM-F12
medium (1:1) was added to the cells to stop the reaction at
each 24-h interval until 96 h. Briefly, 25 μl of the samples
was used to measure cAMP levels. cAMP accumulation
was measured in the supernatants, as described previously
with some modifications (28). cAMP was determined by
radioimmunoassay using the acetylation protocol (29).
High-affinity rabbit anti-cAMP antibody was raised in our
laboratory by using BSA-conjugated cAMP. Succinyl-cAMP
tyrosine methylester (ScAMP-TME) was iodinated by the
chloramine-T method (30). Mono- and di-iodo ScAMP-TME
were used as tracer ligands for radioimmunoassay and they
were then purified by gel-filtration chromatography (Sephadex
G 25 superfine), equilibrated and eluted with 1 M sodium
acetate (pH 5.0). Results are given as pmol/ml.
Transmission electron microscopy. Harvested spheroids were
fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer and post-fixed in 1% osmium tetraoxide in 0.1 M
sodium cacodylate buffer for 1 h at 4˚C. Cells were incubated
in 1% uranyl acetate for 1 h at 4˚C, dehydrated in a graded
acetone series and embedded in Epon 812. Samples were cut
on a microtome (Leica MR 2145, Heerbrugg, Switzerland)
and 70-nm thick sections were mounted on copper grids.
They were stained with 5% uranyl acetate and counterstained
with Reynold's lead citrate. Sections were examined with a
Jeol-Jem 1011 transmission electron microscope.
Scanning electron microscopy. C6 glioma cells were seeded
on microslides in 24-well cultures plates containing 1 ml
DMEM-F12 medium at a concentration of 5x104 cells/well.
After attachment of the cells, drugs in a concentration of
10 μM alone and in combination, were applied to cells. Cells
were fixed with 2.5% glutaraldehyde in 0.1 M sodium caco-
dylate buffer (pH 7.4) for 1 h at 4˚C at the 24 and 72 h. Cells
were washed twice for 10 min with 0.1 M sodium cacodylate
buffer and post-fixed in 1% osmium tetraoxide for 1 h at 4˚C.
Cells were dehydrated in graded acetone series and incubated
in amyl acetate. Microslides were critical-point dried, sputter
coated with gold-palladium and observed by SEM (Jeol-
JSM-5200; Jeol, Tokyo, Japan) Photographs were taken at
25 kV using various magnifications and angles.
Statistical analysis and determination of synergism. SPSS
12.0 statistical software (SPSS, Inc., Chicago, IL, USA) was
used for the statistical analysis. The statistical comparison
of all results, except for cAMP levels, were analyzed by
using the Student's t-test. Alterations in cAMP levels were
analyzed by one-way ANOVA test with post hoc analysis
using Tukey HSD at the 24 h and the Welch test with Dunnett
T3 test at the 72 h. Data are represented as the mean ± SEM
or SD, as appropriate, for at least three separate experiments.
Results were considered significant with p<0.0005, p<0.001,
p<0.01 and p<0.05.
Synergy was determined as described previously (31-33).
By this method, synergism was detemined using the following
equation: CI= (D1)/(DX)1+(D2)/(DX)2, where D1 is the tested
concentration of IM used in combination with CIMP, D2 is
the tested concentration of CIMP used in combination with
IM, DX is the concentration of IM alone and (DX)2 is the
concentration of CIMP alone. A CI value of 1 indicated an
additive effect, a CI value <1 indicated a synergistic effect
and a CI value >1 suggested an antagonistic effect.
Results
Cell proliferation. The effects of single and combination
drugs on cell proliferation of C6 glioma is shown in Fig. 1A.
The cell number of the control group showed a proportional
increase as a function of incubation time up to 96 h. In
comparison to the control group, all drug treatments reduced
the number of cells at all times throughout different rates.
Treatment of cells with IM and CIMP resulted in a potent
reduction in the number of cells after 72 h by 54 and 87%,
respectively (p<0.001 and p<0.0005, respectively). The
combination of IM and CIMP caused a 45, 81, 89 and 87%
reduction for different times of incubation (p<0.05, p<0.01,
p<0.001 and p<0.01, respectively). The reduction values of
IM and the combination group were different from each
other after the first 24 h (p<0.01, p<0.05 and p<0.0001,
respectively). In contrast, the reduction in the number of cells
following CIMP treatment and the combination group was
different  from each other only at 48 h following treatment
(p<0.05).  The inhibition by the combination group on cell
proliferation  was synergistic at 96 h.
Cell viability. The cell viability of the group was 90% at
24 h and up to 99% at 96 h. Both single and combination
treatments reduced the cell viability through 48 h; the most
effective in reducing cell viability was the combination group
(13%, p<0.05). After 48 h, all drug treatments lost their
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inhibitory effect on cell viability and the percentage of trypan
blue-positive cells were the same and/or similar to the control
group and to each other (97, 97 and 96% at the 96 h for the
IM, CIMP and combination groups, respectively; Fig. 1B).
Cell cycle kinetics
DNA synthesis (S-phase) analysis of monolayer cultures. Cells
with red-stained nuclei were considered BrDU-positive. As
shown in Fig. 1C, C6 glioma cell nuclei were positive for
BrDU in the control group with BrDU-LI values of 37.53%
at 24 h and 43.26% at 96 h. Treatment of cells with IM and
CIMP resulted in a potent reduction of BrDU-LI values at 48
and 96 h, with values of 69 and 79%, respectively (p>0.05).
Combining IM with CIMP did not have much effect on the
BrDU-LI throughout the 96 h of culture and the potent
inhibition of the BrDU-LI value (87%) persisted at 24 and
48 h (p<0.05). The decrease of BrDU-LI by the combination
represented a synergistic effect at 24 and 72 h.
DNA synthesis (S-phase) analysis for spheroid cultures.
Twenty-five spheroids from all experimental groups, including
the control group, were evaluated for 24 h. Cells with red-
stained nuclei were considered BrDU-positive. The control
group had a healthy pattern of S-phase fraction and many
of the C6 glioma cell nuclei were observed to be positive
for BrDU with a BrDU-LI value of 8.7% (Fig. 2A). In
comparison to controls, IM and CIMP alone reduced the
BrDU-LI values to 3.72 and 2.43%, respectively. In addition,
light microscopy photographs supported this statistical values
that the spheroids of IM and CIMP groups showed less
BrDU-LI positive C6 glioma cells (Fig. 2B and C). When the
combination group was compared with the control group,
a decrease in the BrDU-LI value to 1.96% was observed. In
comparison to the other drug groups, the combination group
seemed to have no significant difference as the BrDU-LI
value was very similar to the CIMP group (Fig. 2D). In
comparison to the controls, either drug treatment alone or
in combination was not statistically significant.
Annexin V-FITC and PI double staining. Fig. 3 clearly shows
different levels of apoptosis induced by the two agents when
used singly. The percentage of apoptotic cells in the IM group
(14.19%) was modestly increased when compared with the
control group (9.82%) at 24 h, but at 96 h treatment with IM
decreased the percentage of the apoptotic cells to 9.09%. In
comparing the control group and the IM group, CIMP potently
induced apoptosis i.e., 35.49 and 80.49% at 24 and 96 h,
respectively. However, when IM with CIMP were used, the
level in combination of apoptosis was enhanced and greater
than additive (61.95%) at 24 h. The percentage of apoptotic
cells induced by the combination group (86.52%) were similar
to the CIMP group (80.49%) at 96 h.
cAMP levels. The cAMP levels of the control group showed a
proportional increase from 8.20 pmol/ml at time 0 to 37.47
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Figure 1. Growth, viability and BrDU-LI of monolayer cultured C6 glioma
cells treated with imatinib and chlorimipramine at a concentration of 10 μM
for 96 h. Cells were initially plated at a seeding density of 5x105 cells per
well. (A) Cell proliferation, (B) Cell viability, (C) BrDU-LI. C, control; IM,
imatinib; CIMP, chlorimipramine; IM+CIMP, imatinib with chlorimipramine.
Results are the mean of 3 different experiments and given as mean ± SE.
Figure 2. BrDU results of the spheroid culture of rat C6 glioma cells at 24 h.
Cells with red stained nucleus were considered BrDU positive. Arrows show
BrDU positive cells. (A) Control group (original magnification, x25), (B)
Imatinib (original magnification, x40), (C) Chlorimipramine (original magni-
fication, x25), (D) Imatinib with chlorimipramine (original magnification,
x25).
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pmol/ml at 24 h and 61.61 pmol/ml at the 72 h. cAMP levels
of the IM group (37.68 pmol/ml) were almost the same as the
control group at 24 h, but IM inhibited cAMP levels similar to
the control (31.26 pmol/ml) at 72 h (p<0.05). In comparison to
the control and IM groups, CIMP potently decreased cAMP
levels to 19.14 pmol/ml at 24 h (p<0.05) and 2.68 pmol/ml at
72 h (p<0.01). The combination of IM with CIMP mildly
decreased the levels to 30.40 pmol/ml at 24 h (p>0.05), but
this group potently decreased cAMP levels to 5.19 pmol/ml
at 72 h (p<0.01). The most potent inhibitory effect among
all drug treatments and time intervals was observed in the
CIMP group (Fig. 4).
Morphology. We discriminated the ultrastructural differences
between the control group and the drug-applied groups by
using TEM and SEM.
Spheroid morphology by TEM
24 h of culture. The control group exhibited normal mor-
phology, characterized by fine texture of nuclear chromatin
defined as oval, heterochromatic nuclei, intact nuclear
membrane, a cytoplasm rich in secretory materials, pro-
portional organelles distributed in the cytoplasm, tubular
structure of mitochondria, intact cytoplasmic membrane,
and many microvilli, which were in contact with other cells
(Fig. 5A). The IM-treated group exhibited a smoothing of the
cell surface, characterized with decreased, short microvilli,
but intact nuclear membrane, pyknotic nuclei, alterations in
mitochondria, as delineated by cristae damage and mito-
chondrial swelling, packaging of small vacuoles, and
presumably autophagic vacuoles with lamellar bodies inside,
and huge vacuoles, which may be the result of small vacuole
fusion. Vacuoles were localized at the peripheral region of
the spheroid (Fig. 5B). Mitochondria which possessed outer
membrane damage and disrupted or lost cristae were observed
in the CIMP group. In addition, presumably autophagic
vacuoles, which were in different dimensions with lamellar
bodies inside were also seen in this group, similar to the
IM group (Fig. 5C). The extension of the nucleus to the
cytoplasm, like a pseudopod, was one of the notable
finding observed. Apoptotic bodies were also observed by
the effect of CIMP. The contact loss of the cells localized
at the proliferation zone was the other effect of the drug. The
combination of IM with CIMP reflected the total effects of
the two drugs displayed when they were administered alone.
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Figure 3. The effects of drugs on C6 glioma cells were discriminated by
flow cytometric data obtained using Annexin V-FITC and PI double stain.
(A) Cells were treated with drugs for a total period of 96 h. Cells were
harvested at 24 and 96 h. The quadrants within the panel shows: bottom
left live non-apoptotic cells (Annexin V negative, PI negative), bottom right
cells in early apoptotic phase (Annexin V positive, PI negative); top right
mid-phase apoptotic (Annexin V positive, PI positive), top left dead/late
apoptotic phase cells (PI positive, Annexin V negative). (B) The percentage
of apoptotic cells is plotted (%). C, control; IM, imatinib; CIMP, chlorimi-
pramine; IM+CIMP, imatinib + chlorimipramine.
Figure 4. The effects of drugs on cAMP levels of C6 glioma cells were
determined by radioimmunoassay using the acetylation protocol. Results
are given as pmol/ml. C, control; IM, imatinib; CIMP, chlorimipramine;
IM+CIMP, imatinib + chlorimipramine.
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Some morphological changes of apoptosis were observed
as nuclear fragmentation, increased autophagic vacuoles,
mitochondrial damage with disrupted outer membrane and
cristae loss and a smooth cell surface (Fig. 5D).
96 h of culture. The presence of a few vacuoles was the only
different morphologic alteration observed at 24 h confined
to the control group. The presence of zonula adherens
(presumably), endoplasmic reticulum and ribosomes was also
noteworthy (Fig. 6A). There were no morphological changes
observed in the endoplasmic reticulum regions and cell
contact with adjacent cells in the IM-treated group. The same
morphological changes were observed as at 24 h, but the
degree of mitochodria damage such as cristae loss, mem-
brane loss, and the number of vacuoles (foamy vacuolated
cytoplasm), including autophagic vacuoles, was increased in
this group at 96 h (Fig. 6B). Vacuole fusions were also
observed. The observed morphologic alterations differed
from those at 24 h and consisted of the increase of
autophagic vacuoles in the CIMP group. Separation of the
cells localized at the proliferation zone was also observed
(Fig. 6C). The combination of IM with CIMP treatment
exhibited morphological changes as cell contact loss at the
proliferative zone of spheroids, invagination of the nuclear
membrane, and the markedly increase in autophagic vacuoles
(Fig. 6D). The presence of big lamellar bodies in the
nucleoplasm and plasma membrane fusion was the most
interesting features which were observed at that time (Fig.
7A and B). The small components of lytic cells which could
be a result of apoptosis were located at the outer part of the
spheroid (data not shown).
Cell morphology by SEM
24 h of culture. The control group of C6 glioma cells had a
spindle-shaped appearance and frequent, active mitotic
division phase was observed under SEM. In the IM group,
cells changed from a spindle-shaped appearance morphology
to random formation to an angular morphology. IM led to
a decrease in the number of microvilli. Some cells in the
IM group possessed cell surface knobs characterized by a
protruding surface. In the CIMP group, some cells possessed
an angular morphology and some cells changed to a globular
appearance like a ball, and CIMP led to a sharp decrease
in the number of microvilli and cell surface extensions. In
the combination group, three different cell types could be
observed as follows: i) a wide body with an angular mor-
phology with short cell surface extensions; ii) a globular
appearance like a ball; and iii) cell surface knobs characterized
by a protruding surface. Apoptotic bodies were prominent in
this group. The presence of three different cell types which
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Figure 5. Transmission electron microscopy (TEM) view of C6 glioma spheroids at 24 h. (A) Control group (original magnification, x7500), (B) Imatinib
group (original magnification, x12000), (C) Chlorimipramine group (original magnification, x15000). One arrow represents the extention of the nucleus to the
cytoplasm like a pseudopod, and wavy arrows represent presumable apoptotic bodies. (D) Imatinib with chlorimipramine. One arrow represents mitochondria
with disrupted outer membrane and two arrows represent mitochondria swelling with criastae damage (original magnification, x12000). av, autophagic vacuole;
ch, chromatin; n, nucleus; mi, mitochondria; mv, microvillus; pn, pyknotic nucleus; v, vacuole; vf, vacuole fusion; vp, package of vacuoles.
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Figure 6. Transmission electron microscopy (TEM) view of C6 glioma spheroids at 96 h. (A) Control group (original magnification, x15000). (B) Imatinib
group (original magnification, x6000). (C) Chlorimipramine group (original magnification, x12000). Wavy arrow represents the separation point of cell from
the proliferation zone of spheroid. (D) Imatinib with chlorimipramine (original magnification, x5000). av, autophagic vacuole; er, endoplasmic reticulum;
n, nucleus; mi, mitochondria; mv, microvillus; v, vacuole; vp, package of vacuoles.
Figure 7. Transmission electron microscopy (TEM) view of C6 glioma spheroids at 96 h. Imatinib with chlorimipramine (original magnification, x4000). (A)
One arrow represents the plasma membrane fusion. Wavy arrows represent presumably the apoptotic bodies. (B) The presence of big lamellar body in the
nucleoplasm (original magnification, x5000). av, autophagic vacuole; cr, remnants of cell; er, endoplasmic reticulum; lb, lamellar body; n, nucleus; nu,
nucleolus; mi, mitochondria; mv, microvillus; v, vacuole; vp, package of vacuoles.
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was observed by the combination group represented the
enhanced cytotoxicity of IM.
96 h of culture. Healthy C6 glioma cells which were in a
spindle-shaped appearance were observed in the control
group (Fig. 8A). In the IM group, many cells possessed an
angular morphology and IM led to a sharp decrease in the
number of microvilli and cell surface knobs, which caused an
appearance like a protruding surface (Fig. 8B). In the CIMP
group, many cells changed to possess a globular appearance
like a ball with short cell surface knobs characterized by a
protruding surface (Fig. 8C). In the combination group, three
different cell types were observed as follows: i) a wide body
with an angular morphology with short cell surface extensions;
ii) a globular appearance like a ball with short extensions;
and iii) no specific appearance with cell surface extensions or
with a protruding surface (Fig. 8D).
Discussion
The treatment of maligant brain tumor glioblastoma multi-
forme with effective chemotherapeutic regimens remains a
challenge. One of the most promising developments in chemo-
therapy has been to substitute cytotoxic agents that inhibit
non-specific targets in cellular pathways that contribute to
carcinogenesis and resistance (25,26). It has been reported
that IM inhibits the growth of glioma cells in preclinical
models, but its poor brain distribution by P-gp limits its
efficacy in patients (34). In this study, we investigated
whether CIMP, which has a specific effect on mitochondria,
could increase the cytotoxic effect of IM.
In the present study, treatment with IM and CIMP in
combination was slightly better than single agents using both
monolyaers and spheroid cultures of malignant C6 glioma
cells. The results of the present study did not fully support
the hypothesis that CIMP could induce a synergistic effect
on IM-induced cytotoxicity. By using a number of different
techniques, the effect of CIMP on IM toxicity on C6 glioma
cells revealed the following: i) the effect of the combination
group on cell proliferation was synergistic at 96 h; ii) the cell
viability results were additive only at 48 h; iii) the decrease
of BrDU-LI represented a synergistic effect at 24 and 72 h;
iv) the decrease in the percentage of spheroid culture cells in
S-phase; v) reduced cAMP levels; and vi) the combination
group represented a synergisitc effect in apoptosis. In addition,
for autophagy, the results varied from IM as single agent to
IM with CIMP in combination and resulted in two different
findings: single IMP treatment led to chemoresistance/cell
survival and the combination of IM and CIMP led to
apoptosis.
The most interesting findings of the present study was
determined by transmission electron micrographs of spheroids
were the apoptosis results. The combination treatment
showed a significant potentiation of apoptosis as compared to
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Figure 8. Scanning electron microscopy (SEM) view of monolayer cultured C6 glioma cells at 96 h. (A) Control group (original magnification, x750), (B)
Imatinib group. Arrow represents cells which possess extended and angular body (original magnification, x750). (C) Chlorimipramine group. Double arrows
represent cells which possess globular appearance like a ball with short cell surface knobs characterized by protruding surface (original magnification, x1000).
(D) Imatinib with chlorimipramine. Long arrow indicates the cell type which possesses no specific appearance with protruding surface (original
magnification, x1000).
829-839  29/2/08  17:07  Page 836
single agent treatment alone and the alteration of autophagic
vacuole-like structures under CIMP treatment. There are no
previous reports on the effect of CIMP on autophagy and our
data link, for the first time, the process of autophagy with the
mode of action of CIMP. Another interesting finding came
from the micrographs of CIMP, when CIMP was applied with
IM, the cell membranes fused to form a unique membrane
surrounding the spheroid exterior (Fig. 6A). The increased
autophagy and the presence of membrane fusion in the
combination group could be interpreted as synergistic.
Another noteworthy finding from the transmission
electron micrographs was the effects of IM, CIMP and the
combination group on apoptosis in C6 glioma cells by using
Annexin V-FITC and PI double staining. Results showed that
IM increased the fraction of apoptotic cells very slightly and
CIMP markedly induced and increased apoptosis at all time
intervals. However, the findings with the combination group
were somewhat surprising; although a low apoptotic fraction
in the IM group and a high apoptotic fraction in the CIMP
group were observed, the weak effect of IM on the induction
of apoptosis, in accordance with the results of transmission
electron micrographs, interest was increased by CIMP in the
combination group. The effect of CIMP on the apoptotic
index was more potent when it was combined with IM. These
findings suggested that the two drugs synergize with each
other. In addition to TEM micrographs of spheroids, the
scanning electron micrographs of monolayer cultured cells
supported the increase in the apoptotic index by the
combination group. These findings supported the synergistic
effect of CIMP on IM-induced toxicity.
In addition, the alterations in cAMP levels of cells also
supported the morphologic findings about CIMP-induced
mitochondrial damage. C6 glioma cells possess native
functional PDGFRs, proliferate in response to PDGF, whose
stimulation leads to a well-expressed cAMP and is the first
identified second messenger (35,36). The different receptors,
chiefly the G-protein coupled receptors and growth factor
receptors are responsible for cAMP accumulation in cells
that cause different physiologic outcomes, and changes in
cAMP levels effect the selective activation of cAMP-depen-
dent protein kinase-A isoforms. The chief source of cAMP is
from ATP, which is generated by mitochondria (37,38). In
our study, the effective inhibiton of cAMP levels was
observed with the CIMP group for all time intervals, but IM
showed its inhibitory effect at 72 h. The inhibitory effect of
the combination group on cAMP levels also increased at 72 h.
The alterations of cAMP levels could also be interpreted as
the inhibitory effect of IM on growth factor receptors, such
as PDGFR.
Spheroids are known to be in vivo-like tissue-culture
representatives and the most adapted model to keep the
in vitro resistance properties of cells. Spheroids more closely
mimic the real biologic environment by providing cell-to-cell
adhesion and signalling. Due to these characteristics,
spheroids quite realistically represent the results of the drug
effects by including limitations in penetration, distribution,
and feedback mechanisms in cell signaling (39,40). In this
study, similar to the BrDU-LI results of monolayer cultures,
all drug applications reduced the BrDU-LI in comparison to
the controls. In comparison to the effects of singly applied
drugs, little more decrease in BrDU-LI was observed in the
combination group. The effect of CIMP could not be defined
as antagonistic, additive, or synergistic, although a strong
synergistic effect was observed in transmission electron
micrographs of spheroids. The prominent morphologic
changes were observed in the spheroid micrographs, but the
combination group seemed ineffective in reducing cells in
S-phase. Because spheroids are the bridge between in vitro
and in vivo, these findings suggest that further studies
(i.e., high dose applications) should be done to achieve the
effectiveness of these drugs in the spheroid model.
Alterations of spheroid morphology revealed that IM
induced and increased the cellular autophagy machinery in
our study. Taken together, in the present study, especially in
light of findings of electron micrographs with Annexin V-
FITC and PI double staining and cAMP results together, the
effect of IM could be interpreted in two different ways: i)
three different studies regarding the IM effect on autophagy
were done by Ertmer et al (41) and Carew et al (42,43).
Ertmer et al (41) described, for the first time, the process of
autophagy with the mode of action of IM. They considered
that autophagy may promote apoptosis in cancer cells. They
revealed that the IM dose-dependently activates the cellular
autophagy machinery in mammalian cells, independently of
tissue type, species origin, or the immortalization status of
cells. When IM was used in combination, the induction of
autophagy by IM might represent an additional mechanism
to induce apoptosis in C6 glioma cells, like the study of
Ertmer et al (41). Besides, if the mode of action of CIMP
was evaluated, the induction of autophagy by CIMP might
represent an additional mechanism of CIMP to induce growth
arrest and promote apoptosis in C6 glioma cells and this
effect of this drug was prominently seen in the combination
group. ii) In contrast to Ertmer et al (41), Carew et al (42,43)
considered that autophagy may promote cancer cell survival
and play important roles in chemoresistance of cancer to
some therapeutic agents, which typically induce an apoptotic
response. They showed that disrupting autophagy augmented
the anticancer activity of the histone deacetylase (HDAC)
inhibitor suberoylanilide hydroxamic acid (SAHA) in IM-
refractory chronic myelogenous leukemia (CML) and in
IM-resistant primary CML cells from patients bearing
mutations in Bcr-Abl, including the T315I mutation that
causes resistance to currently utilized tyrosine kinase inhibitors
and translates into a very poor clinical prognosis (41,42).
When IM is used singly, as shown by Carew et al (42,43)
the induction of autophagy in the IM-applied group might
represent chemoresistance of C6 glioma cells to this
drug.
In contrast to the findings of electron micrographs,
Annexin V-FITC and PI double staining, cAMP levels, cell
viability, and proliferation (Fig. 1A and B), and the BrDU-LI
of spheroids (Fig. 2) did not indicate that the combination
is more potent than the single agent alone, with minor
exceptions. The findings that showed the efficiency of the
combination group vs. single applications could be hypo-
thesized to be related to CIMP's action: CIMP penetrates
plasma membranes easily because of its lipophilic structure
(44). Xia et al (45) showed that CIMP induced apoptosis
in CML HL-60 cells via increased ROS generation, which
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was followed by an increase of caspase-3 activity. They
proposed that CIMP enhanced the level of ceramide which
was involved in ROS production by interacting with complex
III of the ETC. Likewise, Xia et al (45) and Levkovitz et al
(46) found CIMP to induce apoptosis in C6 glioma caspase-3-
like activation and cyt-C-release. Daley et al (47) studied the
mode of action of CIMP in primary cultures of glioblastoma
taken from human biopsies and found that CIMP killed cells
through inhibiting glioma cell oxygen comsumption by
binding complex III, resulting in caspase-3 activation. In the
present study, CIMP could kill C6 glioma cells through a
mitochondria-dependent fashion, as indicated in studies
above. P-gp is a transmembrane protein that engages in drug
efflux in an ATP-dependent fashion. This transports serine or
threonine phosphorylation sites which were phosphorylated
by several kinases such as PKC- and cAMP-dependent
protein kinase (46). IM is a substrate for P-gp (12). CIMP
inhibited ATP production via inhibition of mitochondrial
respiration and this resulted in the inhibition of cAMP
production. In the present study, CIMP was able to faciliate
the penetration of IM through the inhibition of P-gp.
Although, CIMP is not considered as a typical chemo-
therapeutic drug, the present study did not completely
substantiate the synergistic cytotoxic effect of IM combined
with CIMP on C6 glioma cells and a spheroid model. Briefly,
CIMP appears to act with IM only in monolayer cultures of
C6 glioma cells, with few exceptions. Further studies should
be done to provide the basis for a possible use of IM and
CIMP in combination in vivo and to consider CIMP as ‘a
promising compound’ for overcoming IM resistance in the
treatment of glioblastoma.
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